7,8-Dihydroxyflavone TrkB Receptor Activation for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurologic and neuropsychiatric disorders, such as depression and obesity, face challenges due to the in vivo instability of neurotrophin peptide therapies and the need for effective TrkB receptor activation.
Innovation Solution
Administration of 7,8-dihydroxyflavone or its derivatives to activate the TrkB receptor, which are effective in treating neurological disorders, neuropsychiatric disorders, and metabolic disorders by promoting neuroprotection and modulating appetite and metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotrophin peptide therapy (BDNF) is used to treat neurologic and neuropsychiatric disorders, then therapeutic efficacy is improved, but in vivo instability worsens
Solution Approach 1:
The patent creates small molecule copies (7,8-dihydroxyflavone and derivatives) that mimic the biological activity of BDNF peptide. These synthetic flavone compounds replicate the ability to activate TrkB receptors and produce therapeutic effects without the instability problems of the original peptide therapy.
Solution Approach 2:
The patent changes the chemical parameters from peptide-based therapy to small molecule flavone compounds. This fundamental parameter change transforms the therapeutic agent from an unstable peptide that degrades in vivo to a stable small molecule with improved pharmacokinetic properties while maintaining TrkB activation capability.
2Productivity
If TrkB receptor activation is achieved for treating metabolic disorders, then appetite suppression and weight loss are improved, but treatment specificity may worsen
Solution Approach 1:
The patent achieves local quality by designing flavone compounds with specific molecular structures (7,8-dihydroxyflavone core) that selectively target TrkB receptors. The specific substitution patterns and molecular architecture provide localized interaction properties that enhance binding affinity and selectivity for TrkB over other receptors.
Solution Approach 2:
The flavone compounds serve as intermediary molecules that mediate the activation of TrkB receptors. These small molecules act as intermediaries between the administered drug and the target receptor, enabling controlled and specific activation of downstream signaling pathways involved in appetite regulation and metabolism.
Data Source
AI summary
Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.